![](/img/cover-not-exists.png)
1136PPhase III KEYNOTE-048 study of first-line (1L) pembrolizumab (P) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Asia vs non-Asia subgroup (subgrp) analysis
Tahara, M, Hong, R-L, Wan Ishak, W Z, Yen, C-J, Sriuranpong, V, Takahashi, S, Srimuninnimit, V, Yeh, S-P, Oridate, N, Yang, M-H, Tanaka, K, Nohata, N, Koh, Y, Roy, A, Gumuscu, B, Swaby, R F, NgamphaibVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz252.028
Date:
October, 2019
File:
PDF, 76 KB
2019